Normally I would agree BUT the Covid Trial is only one of a...

Normally I would agree BUT the Covid Trial is only one of a handful of ASX companies that has made it to Human Trialing.

Plenty capitalised on early discover but have lost momentum now the hysteria has subsided...even PAA had a steep climb during the WEHI 1 and WEHI 2 Trials ,lost ground on the day the Biolabs 360 data was announced as that was the same day PAA announced that Elanco would not be completing the Licensing deal with the K9 Oral Lymphoma Treatment 9which to me is a step off point for commercialisation$$ on the way to completing Human Oncology Trials.

An Antiviral that may reduce the Viral Load by 50% in the first 24 Hours possibly reduce the viral load by 95% in 72 hours is GLOBAL NEWS.
You may recall HC did their own announcement (unsponsored) and a Reuters announcement was even picked up by two Traders I know in the Mid West of the States ,, who called that night to discuss!!!

Covid Trials is our nearest catalyst , The MND Trial will attract significant attention,, as this is not a same same drug & there is no current cure for MND available Investors will understand they have to be on board prior to a data read out because if its the Holy Grail for MND or even assists with some form of Stasis halting progression its a Block Buster.. Yes the MND Trial is proposed to be 11 months long zzzzzzzz but its fully funded by MND..

K9 Cancer is a difficult one , IMHO had the Phase II had a larger group of trial dogs we may have been abvle to push for a commercial Phase III where Trial K9 owners pay / contribute to the phase III costs and apply for Interim FDA approval that leads to approval in a year if no major adverse effects reported.

Human Oncology ,, again a long way away proposed for end of 2022? early 2023? all data points to a success here , important to take into account the previous Human Phase I/II yes the capsule was unpallatable , but the results of reducing Tumors and lesions in Trial Patients who had "Failed all standard of care" now imagine this trial we take cohorts with early onset lymphoma? ONJF delivered some spectacular data 3 years ago where MPL had a positive effect on 26 of 30 human cancers.. Now new data surrounding Leukemia ,,,,,

So that brings me back to the Human Covid Trial ,,short sharp and sweet ,,, plenty of Trial Participants , 20,000 plus new ones here today..
As long as our Primary End Point is kept simple,really simple, really really simple , ""MPL Reduces the Viral Load in a Covid Positive Patient ""

From my understanding the Company/Management have been instructed in a "clear" manner from multiple SH including myself that change is required immediately surrounding messaging , the damage has been done already with 2 years of positive Trialing and the SP and consequent Market Cap do not represent the Scientific Data gathered to date and the amount of IP the Company has.. The MC has reduced $70m whilst delivering "yes Buckland" delivering slowly but positive data.
The Company must impart VALUE $$$$$$ to the Investment community and throw of the shackles of being labeled a Research Institute ..

and Yes if a Vet Major walks in with a Big Fat Pen and a even fatter Chq Book then .......... all bets are off ,,, fill your boots....I will be